References from scientific journals

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L; EXCEED Study Group. McInnes IB, et al. Lancet. 2020 May 9;395(10235):1496-1505. doi: 10.1016/S0140-6736(20)30564-X. Lancet. 2020. PMID: 32386593 Clinical Trial.

The safety profiles of secukinumab and adalimumab were consistent with previous reports. Seven (2%) of 426 patients in the secukinumab group and six (1%) of 427 patients in the adalimumab group had serious infections. ...INTERPRETATION: Secukinumab did not meet stat …
The safety profiles of secukinumab and adalimumab were consistent with previous reports. Seven (2%) of 426 patients in the secukinuma …

Adalimumab: A Review in Hidradenitis Suppurativa.

Kim ES, Garnock-Jones KP, Keam SJ. Kim ES, et al. Am J Clin Dermatol. 2016 Oct;17(5):545-552. doi: 10.1007/s40257-016-0220-6. Am J Clin Dermatol. 2016. PMID: 27665300 Review.

This article reviews the clinical efficacy and safety of subcutaneous adalimumab in patients with moderate to severe HS. In clinical trials (PIONEER I and II), a greater proportion of adalimumab than placebo recipients reached HS clinical response (HiSCR) at week 12 …
This article reviews the clinical efficacy and safety of subcutaneous adalimumab in patients with moderate to severe HS. In clinical …

SB5: An Adalimumab Biosimilar.

Frampton JE. Frampton JE. BioDrugs. 2018 Oct;32(5):507-510. doi: 10.1007/s40259-018-0307-0. BioDrugs. 2018. PMID: 30251234 Review.

The safety and tolerability profile of SB5 was similar to that of reference adalimumab, as was the immunogenicity profile. Switching from reference adalimumab to SB5 had no impact in terms of efficacy, safety or immunogenicity. The role of reference adalimumab …
The safety and tolerability profile of SB5 was similar to that of reference adalimumab, as was the immunogenicity profile. Switching …

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB. Kimball AB, et al. N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370. N Engl J Med. 2016. PMID: 27518661 Free article. Clinical Trial.

METHODS: PIONEER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppurativa, with two double-blind, placebo-controlled periods. In period 1, patients were randomly assigned in a 1:1 ratio to 40 mg of adalimumab weekly or …
METHODS: PIONEER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppurativa, with two do …

Adalimumab in the treatment of non-infectious uveitis.

Burek-Michalska A, Turno-Kręcicka A. Burek-Michalska A, et al. Adv Clin Exp Med. 2020 Oct;29(10):1231-1236. doi: 10.17219/acem/125431. Adv Clin Exp Med. 2020. PMID: 33125196 Free article. Review.

The standard treatment for NIU is a local, topical and systemic steroid therapy in combination with immunomodulatory therapy. However, recently, a new drug - adalimumab, which is a tumor necrosis factor alpha (TNF-alpha) inhibitor - was approved by FDA in the treatment of …
The standard treatment for NIU is a local, topical and systemic steroid therapy in combination with immunomodulatory therapy. However, recen …

PF-06410293: An Adalimumab Biosimilar.

Lee A, Shirley M. Lee A, et al. BioDrugs. 2020 Oct;34(5):695-698. doi: 10.1007/s40259-020-00445-8. BioDrugs. 2020. PMID: 32949384 Review.

The tolerability, efficacy, safety and immunogenicity profiles of PF-06410293 were similar to those of EU-sourced reference adalimumab, and switching from reference adalimumab to PF-06410293 appeared to have no impact on safety or efficacy. The role of adalimumab …
The tolerability, efficacy, safety and immunogenicity profiles of PF-06410293 were similar to those of EU-sourced reference adalimumab …

Adalimumab in Chronic Plaque Psoriasis: A Clinical Guide.

Wu JJ, Valdecantos WC. Wu JJ, et al. J Drugs Dermatol. 2017 Aug 1;16(8):779-790. J Drugs Dermatol. 2017. PMID: 28809993 Review.

Here we provide a clinical guide for adalimumab and review existing data on the efficacy and safety of originator adalimumab in moderate-severe chronic plaque psoriasis in adult and pediatric patients. ...Finally, we examine available real-world …

Here we provide a clinical guide for adalimumab and review existing data on the efficacy and safety of originator …


Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.

Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Blauvelt A, et al. J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057360 Free article. Clinical Trial.

BACKGROUND: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. OBJECTIVES: We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with psoriasis trea …
BACKGROUND: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II …

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.

Zhao S, Chadwick L, Mysler E, Moots RJ. Zhao S, et al. Curr Rheumatol Rep. 2018 Aug 9;20(10):57. doi: 10.1007/s11926-018-0769-6. Curr Rheumatol Rep. 2018. PMID: 30094742 Free PMC article. Review.

PURPOSE OF REVIEW: Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. ...Subtle differences in adverse events and clinical responses between the reference and biosimilar products were n …
PURPOSE OF REVIEW: Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of num …

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.

Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW; SYCAMORE Study Group. Ramanan AV, et al. N Engl J Med. 2017 Apr 27;376(17):1637-1646. doi: 10.1056/NEJMoa1614160. N Engl J Med. 2017. PMID: 28445659 Free article. Clinical Trial.

We tested the efficacy of adalimumab in the treatment of JIA-associated uveitis. METHODS: In this multicenter, double-blind, randomized, placebo-controlled trial, we assessed the efficacy and safety of adalimumab in children and adolescents 2 years of age or older w …
We tested the efficacy of adalimumab in the treatment of JIA-associated uveitis. METHODS: In this multicenter, double-blind, randomiz …